SARS-CoV-2 Infection Linked to More Rapid Plaque Growth in Lesions

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 10, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Feb. 10, 2025 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with more rapid progression of coronary artery lesion-based plaque volume, according to a study published online Feb. 4 in Radiology.

Neng Dai, M.D., from Fudan University in Shanghai, and colleagues examined the impact of SARS-CoV-2 infection on coronary inflammation and plaques using coronary computed tomography angiography. Lesions of patients with and without SARS-CoV-2 infection were compared in terms of the quantitative total and compositional percent atheroma volume (PAV) and annualized PAV change, presence of high-risk plaque, and attenuation of lesion-specific pericoronary adipose tissue (PCAT) at baseline and follow-up.

Data were included for 2,108 coronary artery lesions in 690 patients with SARS-CoV-2 infection and 480 lesions in 113 patients without SARS-CoV-2 infection. The researchers found that lesions in patients with SARS-CoV-2 infection demonstrated more rapid progression of overall PAV (0.90 versus 0.62 percent per year) and noncalcified PAV (0.78 versus 0.42 percent per year) compared with lesions in patients without SARS-CoV-2 infection. Despite similar prevalence at baseline, lesions in patients with SARS-CoV-2 infection had a higher incidence of becoming high-risk plaque (21.0 versus 15.8 percent) and higher incidence of PCAT attenuation of –70.1 Hounsfield units or higher (27.1 versus 19.8 percent). A higher risk for target lesion failure was seen in lesions in patients with COVID-19 (10.4 versus 3.1 percent; adjusted hazard ratio, 2.90).

"Our findings suggest that SARS-CoV-2 infection may exacerbate cardiovascular risk by accelerating the advancement of susceptible plaque types and coronary inflammation, thus offering a potential mechanistic rationale for the link between prior SARS-CoV-2 infection and adverse clinical events," the authors write.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-11 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords